<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2D — Myocyte Enhancer Factor 2D</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MEF2D</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myocyte Enhancer Factor 2D</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5q14.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4209" target="_blank">4209</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105509" target="_blank">ENSG00000105509</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/600663" target="_blank">600663</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q01484" target="_blank">Q01484</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Parkinson's Disease, ALS, Huntington's Disease, Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cortex, Hippocampus, Striatum, Cerebellum, Substantia Nigra</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2D — Myocyte Enhancer Factor 2D</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MEF2D</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Myocyte Enhancer Factor 2D</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5q14.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/4209" target="_blank">4209</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105509" target="_blank">ENSG00000105509</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/600663" target="_blank">600663</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q01484" target="_blank">Q01484</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Parkinson's Disease, ALS, Huntington's Disease, Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Cortex, Hippocampus, Striatum, Cerebellum, Substantia Nigra</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
MEF2D (Myocyte Enhancer Factor 2D) is a gene located on chromosome 5q14.1 that encodes a critical transcription factor in neuronal development and function. MEF2D is a member of the myocyte enhancer factor-2 (MEF2) family of transcription factors (MEF2A, MEF2B, MEF2C, MEF2D), which play essential roles in neuronal survival, differentiation, synaptic plasticity, and activity-dependent gene expression["@mao1999"].
The MEF2 family is distinguished by their conserved DNA-binding domain (the MADS box) that recognizes the Mef2 response element (MRE) with the consensus sequence TTATTTATA in the promoter region of target genes. MEF2D is unique among MEF2 family members in that it is expressed at high levels throughout development and into adulthood, with particular importance in mature neurons["@flavell2006"].
The gene is catalogued as NCBI Gene ID [4209](https://www.ncbi.nlm.nih.gov/gene/4209) and OMIM [600663](https://omim.org/entry/600663). The protein product (UniProt Q01484) is a ~507 amino acid transcription factor with multiple functional domains that mediate DNA binding, protein-protein interactions, and transcriptional regulation.
The MEF2D gene spans approximately 110 kb on chromosome 5q14.1 and contains 13 exons. Multiple transcript variants are generated through alternative splicing, producing isoforms with distinct N-terminal domains that may have tissue-specific functions. The human MEF2D gene uses two distinct promoter regions, allowing for complex transcriptional regulation.
The MEF2D protein contains several functional domains:
MEF2D is a key mediator of activity-dependent neuronal survival. It transduces survival signals in response to synaptic activity and neurotrophic factors through several mechanisms[@li2019]:
Anti-apoptotic gene expression: MEF2D promotes the expression of anti-apoptotic genes including Bcl-2, Bcl-xL, and XIAP, which protect neurons from various cytotoxic insults including excitotoxicity, oxidative stress, and mitochondrial dysfunction.
Neurotrophic factor signaling: MEF2D integrates signals from BDNF, NGF, and GDNF, linking neurotrophic support to transcriptional programs that promote neuronal survival and differentiation.
Activity-dependent survival: Synaptic activity enhances MEF2D transcriptional activity, providing a mechanism by which active neurons maintain their survival advantage over less active neighbors.
MEF2D regulates genes involved in synaptic structure and function[@chan2020]:
MEF2D directly regulates genes involved in mitochondrial biogenesis and function[@okamoto2021]:
MEF2D controls a large network of target genes involved in diverse neuronal functions[@satoh2020]:
MEF2D is widely expressed in the brain with high levels in regions important for higher cognitive function:
MEF2D has been strongly implicated in Parkinson's disease pathogenesis[@xu2018]:
Activity reduction: Studies have shown that MEF2D activity is reduced in PD models and in postmortem PD brain tissue. This reduction correlates with dopaminergic neuron loss.
Parkin interaction: MEF2D physically interacts with Parkin and PINK1, proteins mutated in familial PD. This interaction suggests MEF2D may play a role in mitochondrial quality control[@yang2014].
Neuroprotection: Restoring MEF2D function protects dopaminergic neurons from cell death in multiple PD models, making it a potential therapeutic target[@kim2021].
Pathological involvement: MEF2D is found in Lewy bodies in PD brains, suggesting it may be sequestered in these inclusions.
MEF2D dysfunction has been implicated in ALS[@liu2022]:
Gene expression alterations: MEF2D regulates genes important for motor neuron survival. Dysregulation of these genes contributes to motor neuron degeneration[@zhang2015].
Protein interactions: MEF2D interacts with ALS-associated proteins including FUS and TDP-43, potentially leading to its dysfunction.
Therapeutic potential: Enhancing MEF2D activity has shown promise in ALS models, though delivery to motor neurons remains challenging.
MEF2D is implicated in Huntington's disease[@tang2019]:
Transcriptional dysregulation: MEF2D target genes are altered in HD models and patient tissue. This contributes to the characteristic transcriptional deficits.
Pathology: MEF2D is recruited to mutant huntingtin inclusions, potentially sequestering it from its normal functions.
Therapeutic targeting: Modulating MEF2D activity may help correct transcriptional dysregulation in HD.
MEF2D plays complex roles in AD[@wang2020]:
Synaptic gene expression: MEF2D regulates synaptic genes that are downregulated in AD, contributing to synaptic dysfunction.
Activity-dependent dysfunction: Impaired MEF2D activity may contribute to deficits in activity-dependent gene expression observed in AD.
Tau pathology: MEF2D may interact with tau pathology, though the relationship is complex.
MEF2D alterations have been reported in MSA[@chen2021]:
MEF2D functions as both a transcriptional activator and repressor:
Activation: In the presence of coactivators (CBP/p300, Cabin1), MEF2D activates target gene expression. Activity is enhanced by neuronal activity and neurotrophic factor signaling.
Repression: With corepressors (Histone deacetylases, MITR), MEF2D can repress gene expression. This allows for rapid response to environmental signals.
MEF2D activity is regulated by multiple post-translational modifications[@liu2021]:
Phosphorylation: Multiple kinases phosphorylate MEF2D:
Sumoylation: SUMO modification can repress MEF2D activity.
Ubiquitination: Degradation through the ubiquitin-proteasome system regulates protein levels.
MEF2D interacts with numerous proteins:
MEF2D plays important roles in neuroinflammation[@zhou2022]:
Anti-inflammatory effects: MEF2D can suppress pro-inflammatory gene expression in glial cells.
Neuron-glia communication: MEF2D regulates genes involved in communication between neurons and glial cells.
Disease relevance: Altered MEF2D function may contribute to the neuroinflammation observed in multiple neurodegenerative diseases.
Age-related changes in MEF2D[@gao2023]:
MEF2D is a potential therapeutic target[@huang2022]:
The following diagram shows the key molecular relationships involving MEF2D — Myocyte Enhancer Factor 2D discovered through SciDEX knowledge graph analysis: